A special recreational cannabis committee in Massachusetts began talks again on Monday (July 10), following a halt on the discussion regarding the debate of tax as members of the group intend to find common ground and introduce a revised bill.
Debate sparked between the House and Senate leaders, not due to the intended legal nature of cannabis in the state but about the taxing system set to follow the consumption.
The original bill, approved by voters last year, indicated a 10 percent tax on adult-use of cannabis in the state, however a newly passed bill by the House increased the tax to 28 percent. Now it’s up to a special six-member committee to find common ground with this bill.
Recreational cannabis support group hopes new bill includes “only minor changes”
Talks had been delayed and a self-imposed June 30 deadline wasn’t met due to House Speaker Robert DeLeo breaking discussion on the bill, until a state budget was approved and sent to state Gov. Charlie Baker.
According to a report from the AP, Sen. William Brownsberger, a member of this cannabis bill committee, warned about making any predictions on the results from these renewed talks.
The House voted to repeal the law and replace it with a bill that called for raising the tax on legal cannabis sales from 12 to 28 percent and giving local governing bodies such as city councils and select boards more power to prohibit or restrict the opening of retail marijuana stores.
The Senate’s more narrowly focused bill keeps the voter-approved law in effect and calls for no changes in the tax rate or municipal control.
Jim Borghesani, communications director with Yes on 4, a pro-cannabis group that worked on campaigning the cannabis bill during the leadup to the election last year, said the group continues to support the law “passed by voters” with no changes to it.
“We have no insight into the negotiations underway between the House and the Senate, but we hope that whatever bill emerges—if a bill emerges—includes only minor changes to the law passed by voters,” Borghesani told The Investing News Network (INN) in an email.
A report found the proposed tax on recreational cannabis could hinder it becoming more common than the illegal product.
Peter Schwartz, a consultant for Anderson Economic Group, told Marijuana Business Daily the recently proposed 28 percent tax could “short-term boost” to the black market, as occasional consumers wouldn’t be compelled to make the switch.
However, other states with higher tax rates– like Washington and Colorado– have seen consumption continue strong.
Don’t forget to follow us @INN_LifeScience for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Agreement propels development of safe and effective proprietary products and formulations for the emerging psychedelic industry
Optimi Health Corp. (CSE: OPTI) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that effective January 4, 2021, it entered into a lab services agreement with Numinus Wellness Inc. (“Numinus“). Recognized as an early leader in developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), Numinus is aiding Optimi’s mission to further the research and development of Canadian-grown psilocybin-producing mushrooms and related product formulations.
Nextleaf Solutions Provides a Corporate Update and Comments on Financial Results from the First Quarter
Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), the world’s most innovative cannabis processor, is pleased to provide shareholders with the following corporate update:
Nextleaf Comments on Financial Results from Q1 Financials
Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”) reported its second quarter results for the period ended December 31, 2020. A complete set of financial statements and Management’s Discussion & Analysis has been filed at www.sedar.com. All dollar figures are quoted in Canadian dollars.
The second quarter of FY21, saw continued momentum for the Company despite ongoing pandemic related challenges. Net revenue grew 8% to $745,748 from $689,276 versus the same quarter year ago. The Company also saw significant improvement on its bottom line, reducing its net loss by 50% from ($.956) million to ($.481) million, year over year for the quarter, as a result of improved gross margin and cost management efforts. On December 9, 2020, the company announced the closing of the acquisition of substantially all of the assets of Lexaria Canpharm (“Canpharm“), the cannabis products division of Lexaria Biosciences, resulting in the addition of a new B2B Line of Business.
FinCanna Capital – The Only Publicly Traded, Royalty-Focused Company for the Licensed U.S. Cannabis Industry Provides Corporate Update
Royalty Model Provides Access to Early Stage Licenced U.S. Cannabis Companies and Leverage to High-Margin Revenues
FinCanna Capital Corp. (“FinCanna” or the “Company”) (CSE:CALI), a royalty company for the licensed U.S. cannabis industry, is pleased to provide a corporate update further to its recently announced upsized financing of $2 million
Significant progress made as Numinus-sponsored PRIME study on psilocybin-assisted psychotherapy for opioid, stimulant and/or alcohol use disorders enters pre-implementation stage
Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), and Syreon Corporation (Syreon), a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access 1 trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders. Currently in the development stage, the PRIME study will assess the efficacy and safety of psilocybin-assisted motivational enhancement therapy.